- Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
This study looks at a new drug, enfortumab vedotin, for advanced bladder or urinary tract cancer that has spread. It compares it to standard chemotherapy to see if it helps people live longer and improves their quality of life.
For: Locally advanced or metastatic urothelial cancerPortugal · Spain - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
For: Urothelial CancerUnited States · Argentina · Australia